 |
|
Evaluation of CB 1348 in Hodgkin's Disease and Allied Disorders
BERTHA A. BOURONCLE, M.D.;
CHARLES A. DOAN, M.D.;
BRUCE K. WISEMAN, M.D.;
WALTER J. FRAJOLA, Ph.D.
AMA Arch Intern Med. 1956;97(6):703-714.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
It has been clearly established that methylbis (β - chloroethyl) amine hydrochloride (nitrogen mustard) is an excellent supplement to radiotherapy in the treatment of Hodgkin's disease * and is also of some value in other related lymphomas and leukemias. However, it has the disadvantages that it must be administered intravenously, that it produces marked bone marrow depression, and that it causes such side-effects as nausea, vomiting, and malaise.
A chemical derivative of nitrogen mustard without such disadvantages would be extremely useful. Triethylenemelamine (TEM), which may be administered by mouth, is very toxic, and its effect is often incalculable.
Another nitrogen mustard derivative, β-naphthyl-bis (2-chloroethyl) amine (R 48; CB 1048), has proved of some value in Hodgkin's disease, polycythemia rubra vera. and some leukemias.
Russian investigators have synthesized a nitrogen mustard derivative, p-bis (2-chloroethyl ) aminophenylalanine (sarcolysine), which when tested against a variety of animal tumors has exhibited antitumor activity.12
For the
. . . [Full Text PDF of this Article]
Author Affiliations
Columbus, Ohio
From the Herman A. Hoster Research Laboratory, Department of Medicine, Ohio State University, College of Medicine.
Footnotes
Submitted for publication Feb. 13, 1956.
This investigation was supported by a grant from the Dorothy H. and Lewis Rosensteil Foundation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
